AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 7.54 |
Market Cap | 516.66M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.99 |
PE Ratio (ttm) | -3.8 |
Forward PE | n/a |
Analyst | Buy |
Ask | 7.59 |
Volume | 119,001 |
Avg. Volume (20D) | 982,463 |
Open | 7.60 |
Previous Close | 7.20 |
Day's Range | 7.23 - 7.65 |
52-Week Range | 6.90 - 30.99 |
Beta | undefined |
About EYPT
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting...
Analyst Forecast
According to 8 analyst ratings, the average rating for EYPT stock is "Buy." The 12-month stock price forecast is $29, which is an increase of 283.09% from the latest price.
Next Earnings Release
Analysts project revenue of $11.02M, reflecting a -21.44% YoY shrinking and earnings per share of -0.48, making a 45.45% increase YoY.
2 months ago · seekingalpha.com
EyePoint Pharmaceuticals: Low Price And Good Data Create An OpportunityEyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME, with one phase 3 trial ongoing and one more planned for 2025. EYP-1901 demonstrated strong safety...